Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Tax Provisions (2017 - 2025)

Lisata Therapeutics (LSTA) has disclosed Tax Provisions for 11 consecutive years, with -$962000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Tax Provisions fell 20.55% year-over-year to -$962000.0, compared with a TTM value of -$962000.0 through Sep 2025, up 69.25%, and an annual FY2024 reading of -$798000.0, up 65.75% over the prior year.
  • Tax Provisions was -$962000.0 for Q1 2025 at Lisata Therapeutics, down from -$798000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at -$798000.0 in Q1 2024 and bottomed at -$2.3 million in Q2 2023.
  • Average Tax Provisions over 3 years is -$1.6 million, with a median of -$1.6 million recorded in 2023.
  • Peak annual rise in Tax Provisions hit 20.55% in 2025, while the deepest fall reached 20.55% in 2025.
  • Year by year, Tax Provisions stood at -$2.3 million in 2023, then soared by 65.75% to -$798000.0 in 2024, then decreased by 20.55% to -$962000.0 in 2025.
  • Business Quant data shows Tax Provisions for LSTA at -$962000.0 in Q1 2025, -$798000.0 in Q1 2024, and -$2.3 million in Q4 2023.